COMPOSITIONS AND METHODS OF TREATING GLAUCOMA

• US 20150253308A1
• Filed: 05/22/2015
• Published: 09/10/2015
• Est. Priority Date: 05/03/2013
• Status: Abandoned Application

• Current Assignee: Orasis Co.
• Original Assignee: Orasis Co.
• Inventors: Hill, Richard A.
• Application Number:
  US14/720,627
• Publication Number:
  US 20150253308A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: G01N 33/5082 Supracellular entities, e.g. tissue, organisms

Abstract

Methods are disclosed for treating glaucoma by treating a novel target. Methods for treating glaucoma by restoring the filtration capabilities of the endothelial lining of Schlemm'"'"'s canal are provided. A method for identifying compounds capable of restoring the filtration capability of the juxtacanalicular meshwork is also provided.

Claims

1. A method for screening candidate molecules for therapeutic effect, the method comprising:

perfusing an anterior chamber resected from donor eye tissue with a perfusion fluid, such that outflow of the perfusion fluid from the anterior chamber occurs through the trabecular meshwork, Schlemm'"'"'s canal, and the intra-scleral aqueous collector channels;

introducing a candidate molecule into the anterior chamber, wherein the candidate molecule is selected from ascorbic acid conjugates, phosphorylated ascorbic acid, phosphorylated ascorbic acid derivatives, ascorbic acid containing phospholipids, ascorbic acid derivatives containing phospholipid, ascorbic acid containing glycolipid, ascorbic acid derivatives containing glycolipid, or other amphipathic molecules; and

determining one or more measurements of therapeutic effect selected from an amount of candidate molecule uptake into donor eye tissue, a rate of candidate molecule uptake into donor eye tissue, a pressure maintained in the anterior chamber, or a rate of outflow of perfusion fluid from the anterior chamber.

2. The method of claim 1, further comprising:

determining baseline values for the one or more measurements of therapeutic effect after perfusing the anterior chamber with the perfusion fluid, and before introducing the candidate molecule;

determining a second set of values for the one or more measurements of therapeutic effect after introducing the candidate molecule; and

determining whether introducing the candidate molecule resulted in a change from the baseline values.

3. The method of claim 2, wherein the one or more measurements is the rate of outflow of perfusion fluid from the anterior chamber.

4. The method of claim 2, wherein the one or more measurements is the pressure maintained in the anterior chamber.

5. The method of claim 1, further comprising determining the one or more measurements of therapeutic effect using anterior chambers resected from normal eyes and eyes with glaucoma.